For instance, while ASO and CRISPRa methods for Dravet syndrome work to increase SCN1A expression in the context of LoF-mediated haploinsufficiency, these methods would be contraindicated in a recently reported subset of patients with early infantile epileptic encephalopathy in whom GoF SCN1A mutations have been identified.44 As precision medicine remains expensive and time-consuming, this introduces significant logistical and financial hurdles before its systematic introduction into the clinic. The gene discussed is SCN1A; the disease is genetic developmental and epileptic encephalopathy.